In fact, anti-IL6 monoclonal antibodies tocilizumab (already approved for the treatment of CAR T cell-induced cytokine release syndrome), siltuximab and sarilumab are currently being studied in the management of severe COVID-19 [110]. Here, IL6 is linked to COVID-19.